Capitalize on the trend towards Point-of-Care Testing (POCT)

Tel-Array is developing a cancer management sensor system for the point-of-care as the first application of its platform technology. 

cancer-management-sensor-system.jpg

This allows patients and physicians to administer traditionally time and money consuming laboratory tests in the comfort of their homes and clinics at a fraction of the cost. This may translate into more regular and frequent testing, leading to:

  • Timely decision making
  • Improved patient prognosis and quality of life
  • Better utilization of public health resources

Point-of-care testing is especially crucial to those in remote rural regions with limited accessibility to laboratory services. 

Tel-Array’s biosensor device will be compatible with all Tel-Array test cartridges, providing flexibility in its use across multiple applications.


Cancer Management

Tel-Array’s cancer management system can concurrently profile multiple cancer protein biomarkers using a sample of unprocessed whole blood from a finger prick.

No additional material or processing steps are needed, and the whole system can be operated by patients and/or physicians. This system also offers a fast time-to-result and a low cost per analysis.

Finally, data transfer to a cloud-based e-Health database is also possible via the smartphone, allowing patients and their physicians to track changes in results over time, as well as for aggregate data analysis of many patients.

Primary use of the management system is as an indicator of relapse and for therapeutic response monitoring. However, applications in drug development and screening (in combination with current practices) are also possibilities.

Breast Cancer

10-Year Prevalence for Selected Cancers (Female, Canada, 2009)

statistic numbers in percentage (%)

Tel-Array is targeting breast cancer as the first disease in its cancer management system.

Breast cancer is the leading cancer for females with 23,800 new cases (26% of all female cases) in Canada in 2013. A woman’s lifetime probability of developing breast cancer is 11.5%. 

Aside from high incidence levels, breast cancer generally has low mortality rates. This leads to a high prevalence of breast cancer patients and survivors who can benefit from more regular testing for indicators of relapse.

In addition, there is good understanding of the disease and its biomarkers in the scientific and medical community. Some guidelines for current clinical use of breast cancer biomarkers include:

  • Every 2-4 months during the initial 5 years, and less frequently thereafter (European Group on Tumor Markers)
  • For metastatic breast cancer follow-up (BC Cancer Agency)

These guidelines are expert opinion-based and take cost considerations into account. With a reduction in testing costs using Tel-Array’s cancer management system, Tel-Array believes there will be more widespread use of cancer protein biomarker testing.

Other Cancers

Tel-Array is actively exploring additional cancer protein biomarkers to complement its cancer management system.


Cardiovascular Disease Management

Cardiovascular disease is the number one disease in Canada, the US and Europe, and the associated social impacts on morbidity, mortality and healthcare costs are profound.

Blood protein biomarker testing is standard of care for cardiovascular disease, in particular for myocardial infarction, or ‘heart attack’.

Using Tel-Array’s biosensor platform technology, this testing can be done at the point-of-care with the same accuracy and sensitivity as central laboratory systems. This will allow cardiac patients to test themselves frequently for indications of a propensity for an upcoming cardiac event.

Tel-Array is currently developing a test cartridge specific for cardiovascular disease.